These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36213358)

  • 21. The use and interpretation of competing risks regression models.
    Dignam JJ; Zhang Q; Kocherginsky M
    Clin Cancer Res; 2012 Apr; 18(8):2301-8. PubMed ID: 22282466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why we should take care of the competing risk bias in survival analysis: A phase II trial on the toxicity profile of radiotherapy for prostate cancer.
    Tullio A; Magli A; Moretti E; Valent F
    Rep Pract Oncol Radiother; 2019; 24(6):511-519. PubMed ID: 31516397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients.
    de Glas NA; Kiderlen M; Vandenbroucke JP; de Craen AJ; Portielje JE; van de Velde CJ; Liefers GJ; Bastiaannet E; Le Cessie S
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26614095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient death as a censoring event or competing risk event in models of nursing home placement.
    Szychowski JM; Roth DL; Clay OJ; Mittelman MS
    Stat Med; 2010 Feb; 29(3):371-81. PubMed ID: 20014354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model.
    Austin PC; Latouche A; Fine JP
    Stat Med; 2020 Jan; 39(2):103-113. PubMed ID: 31660633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marginal semiparametric transformation models for clustered multivariate competing risks data.
    He Y; Kim S; Mao L; Ahn KW
    Stat Med; 2022 Nov; 41(26):5349-5364. PubMed ID: 36117139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating sample size in the presence of competing risks - Cause-specific hazard or cumulative incidence approach?
    Tai BC; Chen ZJ; Machin D
    Stat Methods Med Res; 2018 Jan; 27(1):114-125. PubMed ID: 26711503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A new perspective of survival data on clinical epidemiology: introduction of competitive risk model].
    Nie ZQ; Ou YQ; Qu YJ; Yuan HY; Liu XQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Aug; 38(8):1127-1131. PubMed ID: 28847068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A note on competing risks in survival data analysis.
    Satagopan JM; Ben-Porat L; Berwick M; Robson M; Kutler D; Auerbach AD
    Br J Cancer; 2004 Oct; 91(7):1229-35. PubMed ID: 15305188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kaplan-Meier survival analysis overestimates cumulative incidence of health-related events in competing risk settings: a meta-analysis.
    Lacny S; Wilson T; Clement F; Roberts DJ; Faris P; Ghali WA; Marshall DA
    J Clin Epidemiol; 2018 Jan; 93():25-35. PubMed ID: 29045808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methods of competing risks analysis of end-stage renal disease and mortality among people with diabetes.
    Lim HJ; Zhang X; Dyck R; Osgood N
    BMC Med Res Methodol; 2010 Oct; 10():97. PubMed ID: 20964855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Competing risks in epidemiology: possibilities and pitfalls.
    Andersen PK; Geskus RB; de Witte T; Putter H
    Int J Epidemiol; 2012 Jun; 41(3):861-70. PubMed ID: 22253319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nomogram to Predict Cause-Specific Mortality in Patients With Surgically Resected Stage I Non-Small-Cell Lung Cancer: A Competing Risk Analysis.
    Zhou H; Zhang Y; Qiu Z; Chen G; Hong S; Chen X; Zhang Z; Huang Y; Zhang L
    Clin Lung Cancer; 2018 Mar; 19(2):e195-e203. PubMed ID: 29153966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Competing risk bias in Kaplan-Meier risk estimates can be corrected.
    van Walraven C; Hawken S
    J Clin Epidemiol; 2016 Feb; 70():101-5. PubMed ID: 26327491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Proportional Hazards Regression Model for the Sub-distribution with Covariates Adjusted Censoring Weight for Competing Risks Data.
    He P; Eriksson F; Scheike TH; Zhang MJ
    Scand Stat Theory Appl; 2016 Mar; 43(1):103-122. PubMed ID: 27034534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Propensity-score matching with competing risks in survival analysis.
    Austin PC; Fine JP
    Stat Med; 2019 Feb; 38(5):751-777. PubMed ID: 30347461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved confidence intervals for a difference of two cause-specific cumulative incidence functions estimated in the presence of competing risks and random censoring.
    Scosyrev E
    Biom J; 2020 Oct; 62(6):1394-1407. PubMed ID: 32227361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of delayed graft function on graft and patient survival in kidney transplantation: an approach using competing events analysis.
    Fonseca I; Teixeira L; Malheiro J; Martins LS; Dias L; Castro Henriques A; Mendonça D
    Transpl Int; 2015 Jun; 28(6):738-50. PubMed ID: 25689397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transplant as a competing risk in the analysis of dialysis patients.
    van Geloven N; le Cessie S; Dekker FW; Putter H
    Nephrol Dial Transplant; 2017 Apr; 32(suppl_2):ii53-ii59. PubMed ID: 28340227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct likelihood inference and sensitivity analysis for competing risks regression with missing causes of failure.
    Moreno-Betancur M; Rey G; Latouche A
    Biometrics; 2015 Jun; 71(2):498-507. PubMed ID: 25761785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.